



Surgical Oncology Track

Monday 24 September 2007

08:00 - 08:45 **Teaching Lecture**

Multidisciplinary treatment of locally advanced rectal cancer

Chair: José María Tabernero Caturla, Spain

Speaker: T. Wiggers, The Netherlands

08:00 - 08:45 **Teaching Lecture**

Perioperative chemotherapy in operable NSCLC: a critical review

Chair: Ferran Cardenal, Spain

Speaker: J. Van Meerbeeck, Belgium

08:00 - 08:45 **Teaching Lecture**

Laparoscopic radical prostatectomy

Chair: Joan Morote, Spain

Speaker: V Pansadoro, Italy

08:00 - 08:45 **Teaching Lecture**

Standard of care for patients with locally advanced head and neck cancer

Chair: José M del Campo, Spain

Speaker: J.L. Lefebvre, France

09:00 - 10:30

Opening session

Chair: John F. Smyth, United Kingdom

Speaker: José Baselga, Spain

Speaker: A.M.M. Eggermont, The Netherlands

Speaker: Yvonne Wengström, Sweden

Translating basic research into patient benefit: The druggable cancer genome.

Speaker: Paul Workman, United Kingdom

Moving cancer treatment into the 21st century

Speaker: M. Piccart, Belgium

12:30 - 14:30

Presidential session

European Oncology 2020

Speaker: P. Boyle, France

Speaker: Kapil Dhingra, USA

Speaker: Else Borst Eilers, The Netherlands

Speaker: K. Redmond, Italy

13:30 - 14:30

Special session

Increasing sensitivity of whole body imaging in oncology - a blessing or a curse?

Chair: Heinz P Schlemmer, Germany

Increasing sensitivity of body imaging in oncology – a blessing or a curse? Expectations of the oncologist.

Speaker: I. Judson, United Kingdom

Whole-body MRI

Speaker: Heinz P Schlemmer, Germany

PET/CT: improved sensitivity and specificity in staging and therapy monitoring

Speaker: Gustav von Schulthess, Switzerland

- 13:30 - 14:30 **Special session**
- Retroperitoneal sarcoma**
Chair: Ole S. Nielsen, Denmark
- Surgical standards of treatment**
Speaker: Peter Hohenberger, Germany
- Is there a rationale for pre or postoperative radiotherapy or chemotherapy?**
Speaker: Ole S. Nielsen, Denmark
- Contribution of pathology to decision-making in retroperitoneal sarcoma**
Speaker: Judith V.M.G. Bovee, The Netherlands
- 13:30 - 14:30 **Special session**
- The management of neck nodes**
Chair: Marc Hamoir, Belgium
- Sentinel node biopsy: a diagnostic or therapeutic procedure?**
Speaker: David Soutar, United Kingdom
- Planned neck dissection after chemoradiation for advanced head and neck cancer. Is it always indicated?**
Speaker: Marc Hamoir, Belgium
- 14:45 - 16:45 **Symposium**
- Adjuvant treatment of colon cancer**
Chair: P. Rougier, France
- Open surgery for colorectal cancer – quality assurance**
Speaker: L. Pahlman, Sweden
- Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer**
Speaker: Heidi Nelson, USA
- Adjuvant treatment of stage II colon cancer**
Speaker: P. Rougier, France
- Adjuvant treatment of stage III colon cancer**
Speaker: Claus-Henning Köhne, Germany
- 17:00 - 17:45 **Award lecture**
- Pezcoller Foundation - FECS recognition for Contribution to Oncology**
Co-chair: John F. Smyth, United Kingdom
Co-chair: Guiseppe Bernardi, Italy
- Perspectives on virus-host interactions and tumour development**
Award Lecturer: Luigi Chieco-Bianchi, Italy

Tuesday 25 September 2007

- 08:00 - 08:45 **Teaching Lecture**
- Small-cell lung cancer: any progress?**
Chair: Enriqueta Felip Font, Spain
Speaker: N. Thatcher, United Kingdom
- 08:00 - 08:45 **Teaching Lecture**
- Localised prostate cancer - new surgical and radiation techniques**
Chair: Antonio Alcaraz, Spain
Speaker: M. Marberger, Austria
Speaker: Vincent Khoo, United Kingdom

08:00 - 08:45 **Teaching Lecture**

Progress in radiotherapy technology for non-radiation oncologists

Chair: Xavier Maldonado, Spain

Speaker: V. Gregoire, Belgium

09:00 - 11:00 **Special session**

The European Society of Surgical Oncology (ESSO)

Chair: C.J.H. van de Velde, The Netherlands

Personalized surgical treatment for colorectal liver metastases

Award Lecturer: Irving Taylor, United Kingdom

Personalized surgical treatment for localised prostate cancer

Speaker: H. van Poppel, Belgium

Personalized surgical treatment for early breast cancer

Speaker: E.J.T. Rutgers, The Netherlands

Personalized surgical treatment for sarcoma

Speaker: Peter Hohenberger, Germany

09:00 - 11:00 **Proffered Papers**

Lung cancer (1)

Chair: J. Jassem, Poland

Co-chair: J. Van Meerbeeck, Belgium

Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Mature results of the SLCG 0008 study

Speaker: Pilar Garrido, Spain

Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Speaker: Janusz Rolski, Poland

Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22 / NVALT 2 / EORTC 08012 multi-centre randomised trial

Speaker: David Giligan, United Kingdom

Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

Speaker: Christian Manegold, Germany

Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer

Speaker: Shilpen Patel, USA

Survival of non-small cell lung cancer patients treated with (chemo)radiotherapy can be predicted by a combination of total tumor volume, number of positive lymph node stations on PET, performance status, gender and radiation dose

Speaker: Cary Dehing, The Netherlands

A prognostic model based on BRCA1 mRNA expression: a new determinant of outcome in early non-small-cell lung cancer (NSCLC)

Speaker: Rafael Rosell Costa, Spain

Phase III study of IV vinflunine (VFL) versus IV docetaxel (DTX) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen

Speaker: J.Y. Douillard, France

09:00 - 11:00

Proffered Papers

Gastrointestinal cancer - colorectal (1)

Randomised phase III study of capecitabine, oxaliplatin and bevacizumab (CAPOX-B) with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim safety analysis
Speaker: Jolien Tol, The Netherlands

5-year overall survival update from the X-ACT trial of capecitabine vs. 5-FU/LV as adjuvant treatment for stage III colon cancer
Speaker: Chris Twelves, United Kingdom

Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer
Speaker: Federico Cappuzzo, Italy

Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial
Speaker: Werner Scheithauer, Austria

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase II study, OPUS
Speaker: Carsten Bokemeyer, Germany

Can we predict the nodal status in primary rectal cancer accurately with USPIO MRI?
Speaker: Geerard Beets, The Netherlands

Preoperative evaluation with virtual colonoscopy (VC) in colorectal cancer (CRC) patients candidates to laparoscopic colon resection (LCR)
Speaker: Andrea Tamburini, Italy

Molecular profiles provide clinical meaningful outcome prediction in stage II colon cancer
Speaker: Robertus A.E.M. Tollenaar, The Netherlands

11:15 - 12:00

Keynote lecture

A systems approach to predictive markers and therapeutic targets
Chair: Paul Workman, United Kingdom

A systems approach to predictive markers and therapeutic targets
Speaker: Joe W. Gray, USA

12:30 - 14:30

Presidential session

Late breaking, Best abstracts

14:45 - 16:50

Educational symposium

Locally advanced, non-metastatic prostate cancer - an interdisciplinary approach
Chair: Thomas Wiegel, Germany

Surgery alone for advanced prostate cancer?
Speaker: H. van Poppel, Belgium

Adjuvant radiotherapy
Speaker: Thomas Wiegel, Germany

Options for increasing PSA after radical prostatectomy
Speaker: Per-Anders Abrahamsson, Sweden

Radiotherapy and hormones
Speaker: D.P. Dearnaley, United Kingdom

Surgery for progression after failed radiation therapy
Speaker: James Eastham, USA

- 14:45 - 16:45 **Symposium**
- FECS/ASCO symposium - what have we learnt from pre-surgical medical therapy in breast cancer ?**
Co-chair: John F. Smyth, United Kingdom
Co-chair: Nancy E. Davidson, USA
- The role of neoadjuvant therapy**
Speaker: G.N. Hortobagyi, USA
- Biological lessons from adjuvant therapy**
Speaker: P.E. Lønning, Norway
- Neoadjuvant antiHER2 therapy**
Speaker: E Winer, USA
- Biological lessons from pre-surgical endocrine therapy**
Speaker: Mitchell Dowsett, United Kingdom

- 17:00 - 17:45 **Award lecture**
- FECS Clinical Research Award Lecture**
to be received
Award Lecturer: C.J.H. van de Velde, The Netherlands

Wednesday 26 September 2007

- 08:00 - 08:45 **Teaching Lecture**
- Treatment of extra hepatic colorectal cancer metastasis**
Chair: Andres Cervantes, Spain
Speaker: Dominique Elias, France
- 08:00 - 08:45 **Teaching Lecture**
- Current management of localised pancreatic cancer**
Chair: Esther Casado, Spain
Speaker: M.W. Büchler, Switzerland
- 09:00 - 11:00 **Proffered Papers**
- Breast cancer - early**
Chair: H. Bonnefoi, Switzerland
Co-chair:
- Results of the UK standardisation of breast radiotherapy (START) trials testing hypofractionation for early breast cancer - on behalf of the START trials centres**
Speaker: Mark Sydenham, United Kingdom
- Predictors of increased risk of breast fibrosis at 10 years with higher radiation dose in the early breast cancer (EORTC "Boost versus no Boost" trial 22881-10882).**
Speaker: Laurence Collette, Belgium
- Concomitant versus sequential chemo-radiotherapy for early breast cancer: meta-analysis of randomized clinical trials (RCTs)**
Speaker: Emilio Bria, Italy
- Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials**
Speaker: Gustavo Viani, Brazil
- Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial**
Speaker: J Baselga, Spain
- A comparison between HER2, p53, PAI-1, angiogenesis and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer**
Speaker: Birgitte Offersen, Denmark

Detection of minimal residual disease (MRD) in peripheral blood of primary breast cancer patients - Translational research in the SUCCESS-Study

Speaker: Julia Jückstock, Germany

Improved chemotherapy delivery in breast cancer patients receiving pegfilgrastim primary prophylaxis compared with current practice neutropenia management – results from an integrated analysis (NeuCuP)

Speaker: Matti Aapro, Switzerland

09:00 - 10:45

Proffered Papers

Melanoma

A phase I/II study to determine the feasibility and efficacy of the triple combination of Oblimersen (OBL), Abraxane (ABX), and Temozolomide (TMZ) in metastatic melanoma.

Speaker: Anna Pavlick, USA

Long-term outcome of 403 patients treated with Ruthenium brachytherapy for choroidal melanoma

Speaker: karijn Verschueren, The Netherlands

Oxidative stress induction: an old idea whose time has come. MOA and clinical correlates of the oxidative stress inducer STA-478

Speaker: A Williams, USA

Ipilimumab (MDX-010) in patients with unresectable stage III or IV malignant melanoma: efficacy and safety data from a phase I trial

Speaker: Jeff Weber, USA

Phase II Randomized, Placebo Controlled Study of Sorafenib in Combination with Dacarbazine in Subjects with Unresectable Stage III or Stage IV Melanoma

Speaker: D.F. McDermott, USA

Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response

Speaker: Omid Hamid, USA

Prognosis depends on micro-anatomic patterns of melanoma micrometastases within the sentinel node (SN). A multicenter study in 388 sn positive patients

Speaker: Alexander van Akkooi, The Netherlands

11:40 - 12:30

Keynote lecture

Approaches to targeted therapy optimization: The Epidermal Growth Factor Receptor Family as a model system

Chair: T. Tursz, France

Approaches to targeted therapy optimization: The Epidermal Growth Factor Receptor Family as a model system

Speaker: José Baselga, Spain

12:30 - 14:30

Presidential session

Best abstracts

13:30 - 14:30

Special session

Treatment of localised gastric cancer. Preoperative versus postoperative adjuvant treatment

Chair: C.J.H. van de Velde, The Netherlands

Treatment of localized gastric cancer: pre-operative versus post-operative adjuvant treatment

Speaker: David Cunningham, United Kingdom

Gastric cancer: multimodal treatment

Speaker: C.J.H. van de Velde, The Netherlands

14:45 - 16:45

Educational symposium

Approaches to stage IIIB NSCLC

Chair: J. Jassem, Poland

The role of surgery

Speaker: Dominique Grunenwald, France

Advanced Radiotherapy Techniques in Stage IIIB Non-Small Cell Lung Cancer

Speaker: Allan Price, United Kingdom

Paradigms in chemoradiotherapy

Speaker: J. Jassem, Poland

Making the proper choice

Speaker: P Baas, The Netherlands

14:45 - 16:45

Educational symposium

Multidisciplinary treatment of liver metastases

Chair: Bernard Nordlinger, France

Imaging of liver metastases (CT scan, MRI, PET scan)

Speaker: Gina Brown, United Kingdom

Which liver metastases can be considered resectable?

Speaker: W Bechstein, Germany

Multidisciplinary treatment of resectable liver metastases (including chemotherapy associated liver damage)

Speaker: Bernard Nordlinger, France

Objective of chemotherapy for unresectable liver metastases: best response or resection?

Speaker: Alberto F. Sobrero, Italy

14:45 - 16:50

Symposium

Innovations in prostate cancer - preclinical and clinical

Chair: Ziya Kirkali, Turkey

Biological profiling in prostate cancer

Speaker: Jack Schalken, The Netherlands

Image-guided 4D radiotherapy for prostate cancer

Speaker: Joos Lebesque, The Netherlands

Laparoscopic surgery

Speaker: Thierry Piechaud, France

Retropubic surgery

Speaker: Manfred Wirth, Germany

Chemotherapy developments in hormone refractory prostate cancer, ongoing trials in early and advanced disease

Speaker: Ronald De Wit, The Netherlands

17:00 - 18:00

Debate

This house believes that there is a role for surgery in NSCLC stage IIIA N2 disease

Moderator: J. Jassem, Poland

Speaker in favour: Paul Van Schil, Belgium

Seconder: Rafael Rosell Costa, Spain

Speaker against: Françoise Mornex, France

Seconder: Wilfried Eberhardt, Germany

Thursday 27 September 2007

08:00 - 08:45 **Teaching Lecture**

Current management of hepatic cancer

Chair: Jaume Capdevilla, Spain

Speaker: Josep Llovet, Spain

09:00 - 11:00 **Proffered Papers**

Gastrointestinal cancer - noncolorectal

Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

Speaker: Ghassan K. Abou-Alfa, USA

Capecitabine/Cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC): a randomised phase III trial

Speaker: YoonKoo Kang, Korea

Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

Speaker: Salah-Eddin Al-Batran, Germany

Adding external beam to HDR-intraluminal brachytherapy, improves palliation of oesophageal cancer: a prospective randomized, multicentre trial of the International Atomic Energy Agency

Speaker: Eduardo Rosenblatt, Austria

A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer

Speaker: Tomoo Kosuge, Japan

Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: Results of a Phase III trial

Speaker: Virginia Langmuir, USA

Axitinib (AG-013736) and gemcitabine vs gemcitabine in advanced pancreatic cancer: a randomised phase II study

Speaker: Jean-Philippe Spano, France

Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma

Speaker: Josep Llovet, Spain

09:00 - 11:00 **Proffered Papers**

Sarcoma

Impact of Independent Review on Efficacy Outcomes in a Randomised Multicenter Trial of Trabectedin Given by Two Dosing Regimens in Patients (pts) with Progressing Leiomyosarcomas or Liposarcomas (L-Sarcomas)

Speaker: George Demetri, USA

Continuous daily dosing (CDD) study of sunitinib malate (SU) in pts with advanced GIST compares favorably with intermittent dosing

Speaker: J.Y. Blay, France

Assessment of plasma levels of soluble KIT (sKIT) as a potential surrogate marker for TTP in patients (pts) with advanced gastrointestinal stromal tumor (GIST) treated with sunitinib

Speaker: Patrick Schöffski, Belgium

KIT mutations and sunitinib resistance in gastrointestinal stromal tumors (GISTs)

Speaker: Jonathan Alfred Fletcher, USA

Early progression in patients with high-risk soft tissue sarcomas (STS): A phase III randomized prospective trial (EORTC/ESHO intergroup trial) of neoadjuvant chemotherapy with or without regional hyperthermia (RHT)

Speaker: Lars Lindner, Germany

Personalized therapy with Trabectedin (Yondelis®) in advanced pre-treated sarcomas

Speaker: Patrick Schöffski, Belgium

Up to 6 years follow-up of patients receiving Imatinib Mesylate (Glivec) to treat unresectable or metastatic gastrointestinal stromal tumors (GISTs)

Speaker: Heikki Joensuu, Finland

Optical navigation-assisted surgical planning for sarcoma patients receiving pre-operative radiotherapy

Speaker: Fanny Sie, Canada

11:15 - 12:15

Debate

This house believes that we do not need surgery in locally advanced oesophageal cancer

Moderator: J.F. Bosset, France

Speaker in favour: M. Stuschke, Germany

Seconder: D. Hollywood, Ireland

Speaker against: T. Lerut, Belgium

Seconder: H.D. Saeger, Germany

12:30 - 13:45

Presidential session

ECCO 14 take home messages

Chair: John F. Smyth, United Kingdom

Chair: A.M.M. Eggermont, The Netherlands

Speaker: M. Pierotti, Italy

Speaker: Yvonne Wengström, Sweden

Speaker: Irving Taylor, United Kingdom

Speaker: Michael Baumann, Germany

Speaker: Andrea Biondi, Italy